A Form 4 filed on September 4, 2026, disclosed that Timothy Schmid, Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson, exercised stock options and sold the resulting shares on September 2, 2026.

Key Highlights

  • First option exercise: Schmid exercised 11,070 employee stock options at an exercise price of $131.94 per share, acquiring 11,070 shares of Common Stock.
  • Second option exercise: Schmid exercised 22,527 employee stock options at an exercise price of $151.41 per share, acquiring 22,527 shares of Common Stock.
  • Shares sold: Both sets of shares, totaling 33,597 shares, were sold on September 2, 2026, at $274.74 per share.
  • Resulting direct ownership: Following the transactions, Schmid directly held 25,447 shares of Common Stock.
  • Indirect holdings: Schmid also holds 758 shares indirectly through a 401k and 46 shares through an ESOP, both under the Johnson & Johnson Savings Plan.
  • Option grant origin: The exercised options were awarded under the issuer's Long-Term Incentive Plan and vested on the third anniversary of each grant date.

Schmid's Option Exercises and Share Sales at Johnson & Johnson

According to the filing, Timothy Schmid, identified as EVP and Worldwide Chairman of MedTech at Johnson & Johnson (NYSE:JNJ), executed two separate option exercises on September 2, 2026. The first involved 11,070 employee stock options with a conversion price of $131.94, originally granted on February 11, 2022, and expiring February 11, 2029. The second involved 22,527 employee stock options at a conversion price of $151.41, granted on February 10, 2023, and expiring February 10, 2030. The filing notes that both option awards were made under the issuer's Long-Term Incentive Plan and that each "vests and is exercisable on the third anniversary of the grant date."

On the same date, the filing reports that Schmid disposed of all 11,070 shares from the first exercise and all 22,527 shares from the second exercise, both at a sale price of $274.74 per share, using transaction code "S." Following all reported transactions, Schmid's direct beneficial ownership in Common Stock stood at 25,447 shares, according to the filing.

The filing also discloses indirect holdings as of the plan's most recent reporting date of August 31, 2026: 758 shares accrued through dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan (held via 401k), and 46 shares held by an ESOP under the same plan. The form was signed by Joleen Morgan as attorney-in-fact for Timothy Schmid and dated September 4, 2026.

What Was Disclosed

The filing reported the exercise of two sets of employee stock options and the same-day sale of all resulting shares by Johnson & Johnson's EVP Timothy Schmid on September 2, 2026, along with his resulting direct and indirect beneficial ownership positions.